363 results about "Pulmonary disorders" patented technology

The invention discloses a lung CT image segmentation method based on Transform and U-Net, and the method comprises the steps: firstly obtaining a pulmonary nodule CT scanning image, carrying out the preprocessing, then constructing a segmentation model MCSTU-Net, enabling the model to extract abundant features through the fusion of a convolutional neural network and a Swin Transform module, and enabling the segmentation model to obtain a segmentation model MCSTU-Net. Enhancing and fusing feature information from different levels through a multiple attention fusion module; dividing the data set into a training set, a test set and a verification set, training and verifying the segmentation model, and finally performing focus segmentation on the pulmonary nodule CT scanning image by using the trained and verified model. According to the model and the method constructed by the invention, lesion tissues in the lung CT image can be segmented more accurately, the effectiveness of each module is verified through an ablation experiment, and doctors are assisted to diagnose and treat lung diseases.

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention discloses an application of phenyllactic acid or a composition containing phenyllactic acid in preparation of medicines for relieving lung diseases, and in the application, the lung diseases are preferably pulmonary fibrosis or acute lung injury. In an acute lung injury research model, phenyllactic acid can effectively intervene in the inflammatory factor cascade reaction and oxidative stress injury process, and acute lung injury symptoms caused by the factors are remarkably improved. Compared with the traditional treatment means, the experiment proves that the phenyllactic acid or the composition containing the phenyllactic acid can obviously relieve the symptoms of acute lung injury (ALI) of mice induced by lipopolysaccharide (LPS) and pulmonary fibrosis (PF) of mice induced by bleomycin, the pathological change of the lung is effectively improved, and the lung function is recovered.

The invention relates to a bifunctional protein targeting PD-1 and TGF [beta] and application of the bifunctional protein in cancer treatment by combining radiotherapy. Specifically, the present invention relates to the use of a bifunctional protein targeting PD-1 and TGF [beta] in the preparation of a medicament for treating an individual suffering from cancer, the bifunctional protein targeting PD-1 and TGF [beta] comprising: (1) an anti-PD-1 antibody or an antigen binding fragment thereof; (2) an immunoglobulin Fc structural domain; and (3) a TGF-beta R II extracellular domain. The invention further relates to application of the PD-1 and TGF beta targeting bifunctional protein in preparation of drugs for treating or preventing lung diseases or symptoms, especially radiation-induced lung injury, caused by radiotherapy of individuals.

The invention relates to a nano preparation for delivering antibiotics based on plant extracts and application of the nano preparation, and belongs to the technical field of nano preparations. In order to solve the problems of low bioavailability and low action efficiency of oral administration or intravenous injection of antibiotics in the lung disease treatment process, the invention provides a nano preparation for delivering antibiotics based on plant extracts. The mass volume ratio of the antibiotics to the plant extract in the nano preparation is (1-10) mg: (20-100) mu L. The nano preparation disclosed by the invention can obviously inhibit the migration of fibroblasts, has an obvious bacteriostatic effect and can reduce the density of microorganisms in lungs; positive charges carried by the material are combined with negative charges on the surface of a bacterial cell membrane, transmembrane substance transfer on the bacterial cell membrane is affected, bacterial metabolism and reproduction are affected, adjustment of pulmonary symbiotic bacteria is better achieved, and the pulmonary fibrosis progress can be relieved. The nano preparation has the advantages of small toxic and side effects, good patient compliance, high encapsulation efficiency and the like.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The present disclosure provides biomarkers associated with caveolin-1 peptide therapy in subjects with interstitial lung disease. In particular, the present disclosure describes biomarkers such as MYDGF, soluble RAGE, pSMAD2 / 3, and PDGFRβ associated with caveolin-1 peptide therapy in subjects with idiopathic pulmonary fibrosis. These biomarkers could be used to determine efficacy, monitoring, and optimal dosing of caveolin-1 peptide therapy in subjects with interstitial lung disease.

The present invention relates to a pharmaceutical composition in inhalable pre-metered dry powder form that comprises at least one excipient (for example carrier) and at least one active substance used against viral diseases to locally administer it to the lungs for use in the treatment of symptoms of viral lung diseases including COVID-19 caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-COV-2) by means of dry powder inhaler through inhalation. The present invention also relates to methods for preparation of said pharmaceutical composition and the use of these active substances in symptoms caused by COVID-19. similar viral lung diseases, influenza.

The invention provides an application of a polypeptide Nod-T3 in preparation of a medicine for treating lung diseases, the polypeptide Nod-T3 is derived from human protein, has the effect of remarkably inhibiting chronic lung inflammation and fibrosis caused by smoking, can be used for treating COPD and other smoking-related lung diseases, and is high in biocompatibility, small in toxicity, low in cost and suitable for clinical application. The polypeptide has the potential and development value of becoming a novel polypeptide drug.

The disclosure relates to compounds of formula I, wherein X, and R1-R4, n, and m have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I exhibit GPR 183 antagonistic activity and are thus useful in the treatment or prevention of disorder, condition, or disease where GRP183 antagonist is indicated to be useful, such as e.g. chronic pain e.g osteoarthritis, chronic low back pain, neuropathic pain and immune system diseases e.g inflammatory bowel diseases e.g. Colitis and Chron's diseases, multiple sclerosis, rheumatoid arthritis, inflammatory pulmonary diseases e.g. asthma and psoriasis.

Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4 / 5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis, and chronic obstructive pulmonary disorder (COPD).

The invention provides a multi-element machine learning model-based cross-species lung disease characteristic gene screening method and system, an electronic system and a storage device. The method comprises the following steps of: acquiring single cell / transcriptome data related to mouse lung diseases from a public database and preprocessing the single cell / transcriptome data; training the model by adopting six machine learning algorithms and outputting a gene importance score; calculating the weight according to the model performance and normalizing the score; and integrating the cross-species scores through a weighted fusion formula, and outputting a feature gene list and a visual report. The system comprises a data acquisition and preprocessing module, a multi-element machine learning model training module, a weight calculation and normalization module, a cross-species comprehensive scoring module and a result output module. The screening accuracy, stability and generalization ability are improved through multi-algorithm integration and cross-species fusion, and the method can be widely applied to the fields of mechanism research of lung diseases, diagnosis marker development and drug target verification.

Proposed is a composition for preventing or treating lung diseases. The composition may contain CD47-overexpressing mesenchymal stem cells as an active ingredient. CD47-overexpressing mesenchymal stem cells, even when not autologous, show a high survival rate in vivo and the ability to migrate to lung tissue, reduce the inflammatory response in lung tissue, and exhibit a fibrosis-inhibiting effect. CD47-overexpressing mesenchymal stem cells can be widely used for the prevention or treatment of various lung diseases related to inflammation or fibrosis of the lungs.

This therapeutic drug for acute pulmonary disorder comprises, as an active ingredient, extracellular vesicles derived from airway epithelial cells.

The invention relates to the technical field of medical equipment, in particular to a spray dosing device and system for lung diseases, comprising a shell in which a medicine storage bin for storing liquid medicine and an atomizing component for atomizing and spraying the liquid medicine are mounted, the atomization assembly is communicated with the medicine storage bin, the respiration triggering assembly is installed at the end, away from the medicine storage bin, of the atomization assembly, the airflow adjusting assembly is installed in the atomization assembly, and the atomization assembly is communicated with the medicine storage bin. The airflow adjusting assembly is in signal connection with a controller, and the controller is in signal connection with the atomization assembly and the respiration triggering assembly. The system is used for achieving accurate and intelligent spray administration according to the breathing state of a patient, the deposition efficiency of medicine in the lung is improved, the treatment effect is optimized, and formulation of a personalized treatment scheme is achieved.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The invention discloses a method and a system for extracting a region of interest of a lung disease pathology full-slice image, relates to extraction of a region of interest, and aims to solve the technical problem of low accuracy of region of interest extraction in the prior art. Comprising the following steps: acquiring lung image data and calculating a semantic similarity score and a visual representation vector of each block; obtaining an optimal threshold according to the semantic similarity score, and screening out an index set; clustering the visual representation vectors of the blocks in the index set, and selecting the block with the highest semantic similarity score in each cluster as a representative block to obtain the index set; and based on the index set, extracting a feature matrix of each representative block, and backtracking to a space coordinate position of each representative block in the corresponding lung image data through an index to obtain a region of interest. Self-adaptive threshold filtering and recognition are carried out according to the semantic similarity score, and heterogeneity distribution of different wettability characteristics in the slice is reserved in the selected region of interest.

The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, the bacterium H. pylori in a subjects digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.

The present disclosure relates to compounds of formula (I) that are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, for the treatment of heart failure, fibrotic diseases and related diseases, such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease) or liver disease (e.g., non-alcoholic steatohepatitis and portal hypertension). TIFF2025501509000144.tif53146

A system, method, and computer program product for quantification of severity of a lung disease. An example aspect is configured to: provide an image file of a chest x-ray from a patient to a first artificial intelligence system to perform pre-processing of the image, wherein the lung is divided into at least four sections; provide each section to a second artificial intelligence system to generate a first density score and a first extent score of each section to calculate a first RALE score, wherein the second artificial intelligence system generates a density segmentation map of each section to calculate a second density score and a second extent score to calculate a second RALE score; analyze the first RALE score and the second RALE score; and display a result to a user.

The invention relates to the technical field of cell biology, in particular to application of a composition containing a mesenchymal stem cell secretor in pulmonary fibrosis. A systematic pharmacodynamic experiment verifies that the composition can remarkably reduce the content of a key fibrosis promoting factor TGF-beta1 in the blood of a pulmonary fibrosis model rat and effectively improve the blood-gas exchange function at the same time, and the blood oxygen saturation (SaO2) is remarkably increased, and the partial pressure of carbon dioxide (pCO2) is remarkably reduced. The improvement of the key indexes proves that the composition has a definite anti-fibrosis effect and a lung function protection effect, and a brand new treatment strategy is provided for pulmonary fibrosis diseases which lack special-effect treatment clinically at present. The technology not only has a remarkable clinical transformation value, but also develops an innovative research thought for the lung disease treatment field based on the action mechanism of the stem cell secretor, and has important scientific significance and market development prospect.

Disclosed herein are double stranded ribonucleic acids (dsRNAs) and synthetic antisense oligonucleotides (ASOs) for use in inhibiting the expression of MUC5B and in the treatment of a subject having a disease or disorder characterized by overexpression of MUC5B, including in subjects having lung disease or in a subject at risk of developing lung disease, for example, in a subject having or at risk of developing idiopathic pulmonary fibrosis.

Provided are methods and systems for measuring lung function, such as shunt and deadspace, using pulmonary gas exchange in management and treatment of pulmonary diseases including COVID-19.

The invention relates to application of an Artemisia rupestris extract in preparation of medicines for preventing and treating lung diseases. According to the application of the artemisia rupestris extract in preparation of the medicine for preventing and treating the lung diseases, the artemisia rupestris extract is prepared by taking artemisia rupestris as a raw material, and the crude drug concentration is 20-110 mg / mL. The artemisia rupestris extract contains chemical components such as sesquiterpenoids, flavonoids, organic acids and phenylpropanoids. The medicine is a veterinary medicine. The lung diseases comprise allergic pneumonia, pulmonary fibrosis or diseases caused by injury of other lung tissues. The dosage form of the medicine for preventing and treating the lung diseases is a pharmaceutically acceptable dosage form. The pharmaceutically acceptable dosage form is oral liquid, powder, tablets, granules, capsules, pills, syrup, suspension or emulsion. The application defines the prevention and treatment effect of the Artemisia rupestris extract on lung diseases. During application, the artemisia rupestris extract is small in dosage and high in curative effect, and the weight of livestock and poultry can be greatly reduced due to the fact that lung tissue is damaged.